A new machine learning model is able to identify Parkinson’s disease more accurately than other models based on electroencephalography (EEG) readings of the brain’s electrical activity, a study found. “The proposed model holds promising potential as a valuable and enduring aid for experts and clinicians in diagnosing” Parkinson’s, researchers…
News
Rumble Boxing, a U.S. fitness brand, is partnering for the second year with Team Fox, the grassroots fundraising community of The Michael J. Fox Foundation (MJFF), to raise awareness and funds during Parkinson’s Disease Awareness Month this April. Among Rumble’s planned activities is a multicity tour panel…
The first patient has been dosed in a first-in-human trial testing Vanqua Bio’s VQ-101 as an oral therapy for Parkinson’s disease linked to mutations in the GBA gene, the company has announced. The Phase 1 clinical trial is assessing the safety, tolerability, and pharmacological properties of VQ-101 in both…
A widening of tiny, fluid-filled spaces in certain brain regions could be used as an imaging marker of levodopa-induced dyskinesia (LID) in people with Parkinson’s disease, a study showed. Perivascular spaces, or PVSs, were larger in Parkinson’s patients with LID — a condition in which standard Parkinson’s medications…
NeuroVigil has launched its iBrain personal brain monitor — an investigational portable device that can noninvasively record the brain’s electrical activity in people with neurological conditions — in the U.S., according to a company press release. In the second phase of the launch, NeuroVigil will use a smaller…
The first patients received doses of an oral thin-film formulation of montelukast in a clinical trial testing the treatment’s potential for Parkinson’s disease. The placebo-controlled MONTPARK trial will test how well a high dose of Montelukast VersaFilm, a proprietary formulation being developed by IntelGenx, can slow the progression…
DrTalks, a platform that aims to advance wellness and medicine by connecting people with health experts, has set the dates for its virtual meeting in November — dubbed the Parkinson’s Solutions Summit 2.0 — designed to provide insights into how to better manage and treat the progressive neurodegenerative…
Levels of two markers of intestinal inflammation — beta-defensin 2 and lactoferrin — were elevated in the stools of Parkinson’s disease patients when compared with healthy adults, and were associated with a likelihood of developing the disease, a study found. Calprotectin, a marker of tissue inflammation, wasn’t found to…
Anxiety is common among people with Parkinson’s disease and contributes to a worse life quality for patients irrespective of motor symptom severity, according to a new German study. Nearly 40% of the patients in the small study were found to have clinically relevant anxiety — and those with more…
The presence of salt or a molecular crowd may make it more likely for the alpha-synuclein protein, which forms toxic clumps in the brains of people with Parkinson’s disease, to aggregate, or build up, into droplets, according to computer simulations run by researchers in India. Understanding how alpha-synuclein behaves,…
Recent Posts
- The invisible support a Parkinson’s caregiver provides
- US, China regulators OK trials of stem cell therapy in MSA-P
- When caregiver stress hits, I remember to have ‘just a little patience’
- Japan grants conditional approval to Amchepry cell therapy for Parkinson’s
- Good design for those of us with mobility issues is good design for all